Adaptive Biotechnologies (ADPT) CCO Susan Bobulsky Sells 5,000 Shares

What Happened Susan Bobulsky, Chief Commercial Officer of Adaptive Biotechnologies, reported the sale of 5,000 shares on July 16, 2026. The shares were disposed at $23.00 each, for a total transaction value of $115,000. This was a sale (often a routine liquidity event), not a purchase.

Key Details

• Transaction date and price: July 16, 2026 — 5,000 shares sold at $23.00 per share.
• Total proceeds: $115,000.
• Shares owned after transaction: Not specified in this filing.
• Method: Reported as an open-market or private sale (Form 4 codes: S).
• Footnote: The sale was made pursuant to a Rule 10b5-1 trading plan adopted by Ms. Bobulsky on December 16, 2025.
• Filing timeliness: Form filed on July 20, 2026 (appears to be within the standard two business-day Form 4 reporting window for a July 16 trade).

Context Sales executed under a 10b5-1 plan are typically pre-arranged and can be routine; they do not by themselves indicate a change in insider view of the company. Purchases generally carry more weight for signaling, while single open-market sales are often done for diversification or personal-liquidity reasons.